The inventors have discovered a collection of proteinaceous biomarkers (~AD~ biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels.
METHODS AND COMPOSITION FOR DIAGNOSIS OF NEUROLOGICAL DISORDERS IN BODY FLUIDS